Incivo: second hepatitis C protease inhibitor launched

Incivo (telaprevir) is a new oral preparation licensed in combination with peginterferon alfa and ribavirin for the treatment of hepatitis C in both pretreated and treatment-naive adults.

Telaprevir is taken every 8 hours with food
Telaprevir is taken every 8 hours with food

PHARMACOLOGY

Telaprevir is a direct inhibitor of NS3 protease, which is required by the hepatitis C virus for replication.1

CLINICAL STUDIES

Telaprevir has been investigated in 2 studies in treatment-naïve patients ( and ) and 1 study in patients previously treated with peginterferon and ribavirin (). Patients received telaprevir, in combination with peginterferon alfa and ribavirin, for 8 or 12 weeks followed by 12–24 weeks of peginterferon alfa and ribavirin alone, depending on virological response. In all studies, patients who received telaprevir had a significantly higher rate of sustained virological response at 24 weeks after last planned dose of study drug.2–4

REFERENCES

View Incivo drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Drug shortages - live tracker

Drug shortages - live tracker

Added: Muse.
Use our constantly updated shortages...

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury